What insurance does a biotech spinout from an academic institution need?

Biotech spinouts from academic medical centers and universities (MGH, Brigham, Dana-Farber, UCSF, Stanford, MIT, Harvard, Duke, UNC, etc.) face a distinctive insurance starting point. The founding scientists are often dual-employed (university and startup); IP is licensed from the institution under a tech transfer agreement that creates ongoing license-back and milestone obligations; clinical work may run as investigator-initiated studies at the founding institution before transitioning to sponsor-led trials.

Each of these structural features has insurance implications that pure-startup biotechs do not face. The technology transfer office at the founding institution typically requires specific insurance terms as a condition of license or option, and those terms persist through the life of the license.

D&O sized to the dual-board governance reality. Many academic spinouts have a board that includes representatives of the founding institution alongside investor directors and founder/scientific directors. The mix produces concentrated governance risk: founder-investor disputes, IP-licensing disputes with the founding institution, and clinical-decision disputes when the founding institution is also a clinical trial site.

Typical limits $3M-$10M with Side A emphasis. Side A coverage is particularly important because pre-revenue biotechs cannot indemnify directors against institutional disputes that might bar indemnification.

Academic technology transfer agreements typically include milestone obligations, royalty obligations, and a license-back provision allowing the founding institution to continue using the IP for research purposes. Disputes arise when the spinout believes the institution is exceeding license-back scope or when the institution believes the spinout has missed milestones.

IP infringement defense and license-back dispute coverage is sometimes available as part of D&O sub-limits or as a standalone IP policy. Standalone IP defense limits are $1M-$5M typically; pricing is significant for life-sciences operators because the threat profile is well-understood.

Many academic spinouts run their first clinical activity as IIS at the founding institution, with the academic investigator as the IND holder. This creates a hybrid coverage structure: the institution's policies cover the clinical site activity; the spinout's policies need to cover the company's sponsorship contributions (financial support, investigational product if provided, etc.). The IIS support agreement should specify which entity carries clinical trial liability and what additional-insured wording applies.

When clinical activity transitions from IIS to sponsor-led trials, the spinout's CTL program needs to be in place before the transition. Many spinouts discover at the IND-transfer point that their CTL program was not sized for sponsor-led activity.

When the spinout operates out of the institution's incubator space (Cambridge Innovation Center, Mission Bay biotech incubator, RTP biotech facilities, etc.) or uses the institution's core facilities (analytical, sequencing, animal facility) under fee-for-service arrangements, the property and general liability programs need to address shared-facility exposure carefully. Hold-harmless and AI provisions in the facility agreement matter for both directions.

A pre-Series A or Series A biotech spinout at $0-$10M raised typically runs an annual insurance program of $35,000-$120,000 covering D&O, EPLI/fiduciary, cyber, CGL, property, and either CTL or IIS coverage extensions as applicable. The program grows materially with Series B and beyond as clinical activity scales.